| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Friedman Mordechai serves as a Director at BCLI. Across recent SEC filings that breaks down to 0 buys and 1 sell. Those positions are worth an estimated $4K at current prices.
The biggest single holding is BCLI (~$4K) as Director. The recent filings there lean toward selling, a net 5,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 14, 2015 | BCLI Brainstorm Cell Therapeutics Inc. | Director | Sale+OE | 5,000 | $2.57 | $12,850.00 | -100% |